Inventiva (CHIX:IVAP) Other Stockholders Equity: €-0.00 Mil (As of Dec. 2025)


CHIX:IVAP Inventiva SA CHIX:IVAP
53 GF Score
Price €3.06
GF Value €0.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Other Stockholders Equity?

Inventiva CHIX:IVAP 53 Other Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus rates CHIX:IVAP with a GF Score™ of 53/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Inventiva's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €-0.00 Mil.

Inventiva's quarterly Other Stockholders Equity increased from Dec. 2024 (€-0.00 Mil) to Jun. 2025 (€0.00 Mil) but then declined from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Inventiva's annual Other Stockholders Equity declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil) and declined from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Inventiva Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Inventiva's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Other Stockholders Equity Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 -0.00

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00
CHIX:IVAP
53GF Score
Inventiva SA CHIX:IVAP
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.00 Mil mean?
Inventiva (CHIX:IVAP) has a Other Stockholders Equity of €-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Inventiva and its competitors.
Is Inventiva's Other Stockholders Equity too high?
Inventiva's current Other Stockholders Equity is €-0.00 Mil. Overall, Inventiva has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Other Stockholders Equity compare to VRTX and REGN?
Inventiva's Other Stockholders Equity of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Inventiva and its competitors. Inventiva's current Other Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (CHIX:IVAP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.06 — trading 1175% above its estimated fair value. The current Other Stockholders Equity is €-0.00 Mil. Inventiva's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Inventiva (CHIX:IVAP), the current Other Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (CHIX:IVAP) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of €3.06 is trading 1175% above its estimated GF Value™ of €0.24. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for CHIX:IVAP:

  • Other Stockholders Equity: €-0.00 Mil
  • GF Value™: €0.24 vs. price of €3.06 (1175% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the CHIX:IVAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
53GF Score

Get the complete analysis for CHIX:IVAP

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€0.24
GF Value